DIRS.INFO The most relevant business & tech news

☆ Sanofi CEO Paul Hudson on Q1 results: Hope to gather even more momentum later this year
▼ + stars: | 2024-04-25 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailSanofi CEO Paul Hudson on Q1 results: Hope to gather even more momentum later this yearSanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, drug pipeline outlook, and more.

Persons: Paul Hudson, Hope Organizations: Sanofi

☆ Sanofi CEO Paul Hudson: We've got perhaps the world's best immunology pipeline
▼ + stars: | 2024-01-18 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailSanofi CEO Paul Hudson: We've got perhaps the world's best immunology pipelineSanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's plan to become an immunology powerhouse, drug pipeline outlook, using AI for future drug discoveries, and more.

Persons: Paul Hudson, We've Organizations: Sanofi

☆ Sanofi CEO under pressure to woo investors after spending shock
▼ + stars: | 2023-12-05 | by ( Ludwig Burger | ) www.reuters.com time to read: +5 min

[1/2] Paul Hudson, chief executive officer of Sanofi, speaks during the annual results news conference at the company's headquarters in Paris, France, February 4, 2022. The market's shock reaction, compounded by a lack of details of the spending push, overshadowed Sanofi's plan to list its consumer unit, in line with an industry trend. David Song, a portfolio manager and investment partner at Tema ETF, said: "The narrative of Sanofi has been a margin expansion, earnings-driven story for a lot of investors." "Shouldn't investors give credit to managements who care about long-term shareholder value creation?," said Song. ($1 = 0.9206 euros)Reporting by Ludwig Burger; Editing by Josephine Mason and Emelia Sithole-MatariseOur Standards: The Thomson Reuters Trust Principles.

Persons: Paul Hudson, Sanofi, Benoit Tessier, Hudson, Dan Lyons, Janus Henderson, Markus Manns, David Song, Fabian Wenner, Julius Baer, Union's Manns, Janus Henderson's Lyons, Johnson, Song, Ludwig Burger, Josephine Mason, Emelia Organizations: REUTERS, Reuters, Janus Henderson Investors, Germany's Union Investment, Tema, Thomson Locations: Paris, France, British, Hudson, Denver, Swiss, Tema

☆ Sanofi CEO Paul Hudson on Q3 results: Increased R&D spending will impact 2024 profit
▼ + stars: | 2023-10-27 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailSanofi CEO Paul Hudson on Q3 results: Increased R&D spending will impact 2024 profitSanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, spin off of its consumer health care business, growth outlook, and more.

Persons: Paul Hudson Organizations: Sanofi

☆ Sanofi loses $21 billion in market value after dropping 2025 profit target
▼ + stars: | 2023-10-27 | by ( ) www.cnbc.com time to read: +2 min

Chesnot | Getty ImagesSanofi stock plunged on Friday, wiping 20 billion euros ($21 billion) off its market value, after it abandoned its 2025 profit target under a plan to list its consumer healthcare business to focus on its core innovative drugs business. Under a push to spend more on immunology and inflammation drug development, the company abandoned a target for a 32% operating profit margin for 2025 to focus on "long-term profitability." Sanofi shares trade at a 12 month forward price-to-earnings ratio of 11, a discount to AstraZeneca's 16 and global pharma index of 17, according to LSEG data. Bayer, led by a new CEO since June, has faced calls by several investors to split off its consumer business. EPS would see a strong rebound in 2025 but not enough to sustain the previous margin target.

Persons: Sanofi, drugmaker, Paul Hudson, Terence McManus, Kenvue, Johnson, Bayer Organizations: Chesnot, Getty, Sanofi, Bellevue Asset Management, Reuters, Barclays, Johnson, GSK, Pfizer Locations: Gentilly, Paris, France, Bellevue

☆ Investors reject Sanofi's cure to sickly valuation
▼ + stars: | 2023-10-27 | by ( ) www.reuters.com time to read: +3 min

LONDON, Oct 27 (Reuters Breakingviews) - Sanofi (SASY.PA) investors dislike CEO Paul Hudson’s prescription to reinvigorate the pharmaceutical group’s weak valuation. Analysts polled by LSEG expect the division to hit an EBIT of 1.6 billion euros this year. On listed rival Haleon’s 15.6 times multiple, that business could be worth 25 billion euros. The rest of the Sanofi business may generate EBIT of 11.4 billion euros. The problem is that investors don’t appear to want to take the harsh medicine that leads to a cure.

Persons: Paul Hudson’s, Ernst & Young, Sanofi, EBIT, Roche, Karen Kwok, Francesco Guerrera, Streisand Neto Organizations: Reuters, Sanofi, Ernst, LSEG, Novartis, Novo Nordisk, GSK, AstraZeneca, X, Unilever, Thomson

☆ Sanofi loses $21 bln in market value after dropping 2025 profit target
▼ + stars: | 2023-10-27 | by ( Ludwig Burger | ) www.reuters.com time to read: +6 min

Under a push to spend more on immunology and inflammation drug development, the company abandoned a target for a 32% operating profit margin for 2025 to focus on "long-term profitability". EPS would see a strong rebound in 2025 but not enough to sustain the previous margin target. CONSUMER STAND-ALONECEO Hudson said the core innovative drugs business had improved enough to soon do without the more predictable cash flows from consumer products. The logo of French drugmaker Sanofi is seen a the Sanofi Genzyme Polyclonals in Lyon, France, September 30, 2023. The timing of the potential consumer listing, which Sanofi said would be in the fourth quarter of 2024 or later, would be set to maximize shareholder value.

Persons: Hudson, Sanofi, drugmaker, Paul Hudson, Terence McManus, Johnson, we've, Gonzalo Fuentes, Roche, Dupixent, Ludwig Burger, Sherry Jacob, Phillips, Mark Potter, Sharon Singleton Organizations: Sanofi, Bellevue Asset Management, Reuters, Barclays, Johnson, GSK, Pfizer, Bayer, Polyclonals, REUTERS, Provention, Merck & Co, Thomson Locations: France, Bellevue, Lyon, Paris

☆ A Time Capsule Appeared to Be Full of Dirt. Then, They Looked Closer.
▼ + stars: | 2023-08-31 | by ( Livia Albeck-Ripka | More About Livia Albeck-Ripka | ) www.nytimes.com time to read: +1 min

The unveiling of a nearly 200-year-old time capsule yielded great disappointment earlier this week, when the box — opened at the U.S. Military Academy in West Point, N.Y., during a livestream watched by thousands — appeared to contain only dirt. After days of tense speculation, Paul Hudson, the academy’s archaeologist, peered into the roughly one-foot-square lead vessel with a flashlight and soon declared that “the box didn’t quite meet expectations.”As it turned out — Mr. Hudson just had to look closer. After Monday’s event, Mr. Hudson returned the box to his lab. The next day, he dug deeper into the container and unearthed six silver coins dating from 1795 to 1828 and a commemorative medal from 1826, Jennifer Voigtschild, the academy’s command historian, said on Thursday. In the moments after the box was first opened, Ms. Voigtschild said, she felt “baffled that there would be this very, very, well constructed box, that would have nothing in it.” But, she said, as Mr. Hudson began removing pieces of matter from the box while onstage and examining them, her hope was somewhat revived.

Persons: —, Paul Hudson, peered, Hudson, Jennifer Voigtschild, Voigtschild, “ Organizations: U.S . Military Academy Locations: West Point, N.Y

☆ Sanofi CEO Paul Hudson on Q2 results: Our underlying growth is still high-single digit
▼ + stars: | 2023-07-28 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailSanofi CEO Paul Hudson on Q2 results: Our underlying growth is still high-single digitSanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly results after its earnings beat estimates, new drug launches, rest of the year outlook, and more.

Persons: Paul Hudson Organizations: Sanofi

Both sides blame each other for high drug prices. Senator Bernie Sanders, who chairs the Senate Health, Education, Labor, and Pensions (HELP) Committee, is a fierce critic of both industries and will likely grill the executives. Optum Rx CEO Heather Cianfrocco will say manufacturers alone set the drug prices and abuse patent protections to stifle competition, her written testimony shows. Lilly, Novo Nordisk, and Sanofi all said in March they were cutting list prices by more than 70% for some insulin products. Uninsured people often have to pay full list prices, an average of $900 a month, forcing many to ration or skip doses.

☆ Eli Lilly CEO vows not to raise insulin prices again, while Novo Nordisk and Sanofi hedge
▼ + stars: | 2023-05-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Sen. Bernie Sanders, the committee's chair, asked Ricks and the CEOs of Novo Nordisk and Sanofi to commit to "never increase the price of any insulin drug again." Meanwhile, Novo Nordisk CEO Lars Fruergaard Jørgensen said the Danish company is committed to limiting price increases to "single digits." Net price refers to the amount insurers pay for an insulin drug after discounts and rebates. Sanofi said it plans to cut the price of its most popular insulin drug, Lantus, by 78% and reduce the list price of its short-acting insulin, Apidra, by 70%. At the hearing, Sanders called those actions "good news" and a result of public pressure.

☆ Some airlines effectively charge parents to sit with their kids. Biden is shaming the industry into changing that.
▼ + stars: | 2023-04-22 | by ( Brent D. Griffiths | ) www.businessinsider.com time to read: +7 min

Consumer groups and President Joe Biden are aghast that carriers have effectively charged families more to sit together. No airline explicitly imposes a "family seating fee," but consumer advocates have complained for years about how that's exactly what's happening. Airlines for America, an industry lobbying arm that counts the big four, America, Delta, Southwest, and United, among its members, previously pointed out that none of its members explicitly charge a family seating fee. This is a March 24, 2023 screenshot of the Department of Transportation's dashboard of airline family seating policies. Sen. Ed Markey of Massachusetts is working with a trio of other Senate Democrats, including Senate Majority Leader Chuck Schumer, on separate legislation on just family seating.

☆ Eli Lilly, Novo Nordisk and Sanofi CEOs to testify before Senate on lowering insulin prices
▼ + stars: | 2023-04-21 | by ( Spencer Kimball | ) www.cnbc.com time to read: +2 min

In this photo illustration, an insulin pen manufactured by the Novo Nordisk company is displayed on March 14, 2023 in Miami, Florida. Those companies — Eli Lilly, Novo Nordisk and Sanofi — had announced in March that they will slash prices of their most widely used insulin products by 70% or more. The companies' versions of insulin cost at least $275 before the announced price slashes, Sanders noted. Novo Nordisk said its CEO looks forward to "a productive and collaborative discussion about this important issue." PBMs have come under criticism for inflating drug prices and not passing on all the discounts they negotiate to consumers.

☆ Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data
▼ + stars: | 2023-03-23 | by ( Ludwig Burger Jubabu | Ludwig Burger | ) www.reuters.com time to read: +4 min

Sanofi and Regeneron said in a statement on Thursday a Phase III trial involving 939 current or former smokers also showed improvements in lung function, quality of life and COPD respiratory symptoms. JP Morgan analyst Richard Vosser said the trial update had "blow-out data" in store for investors, and that market consensus for 2027 Dupixent sales of 15.7 billion euros would likely be topped-up by between 1 and 2 billion euros. The anti-inflammatory drug accounted for 8.3 billion euros, or more than 19% of the French group's overall sales of 43 billion euros, last year. Sanofi reports combined global Dupixent sales from its alliance with Regeneron. Sanofi and Regeneron on Tuesday announced the European Commission had approved Dupixent to treat severe atopic dermatitis in young children.

March 13 (Reuters) - France's Sanofi SA (SASY.PA) on Monday agreed to acquire Provention Bio Inc <PRVB.O> for $2.9 billion to bolster its work on a U.S.-approved type 1 diabetes therapy and strengthen its drug pipeline following development setbacks. The deal builds on an existing co-promotion agreement between the two companies, and would give the French drugmaker full ownership of the drug, Tzield, Sanofi said, adding it expects to complete the acquisition in the second quarter of 2023. While growth in asthma and eczema drug Dupixent is boosting Sanofi's sales, investors have criticised its drug development pipeline as weak. Sanofi, the maker of long acting insulin products Toujeo and Lantus for type 2 diabetes, in 2019 quit further type 2 diabetes drug development. Chief Executive Officer Paul Hudson said last month the company saw great promise in type 1 diabetes drug development and reaffirmed his commitment to steer clear of further work on type 2 diabetes and obesity.

☆ The FAA won't have to establish seating size and space rules despite all the complaints, US court rules
▼ + stars: | 2023-03-03 | by ( Jordan Hart | ) www.businessinsider.com time to read: +4 min

On Friday, a US court ruled against FAA having to establish minimum seat sizes and spacing for safety, Reuters reports. On Friday, the DC Circuit Court of Appeals ruled that advocacy group FlyersRights.org couldn't force the FAA to adopt seating dimension rules. That is why some passengers pay for wider seats and extra legroom," Walker wrote. There needs to be a minimum size established, and it needs to be larger than the current sizing," commenter Epiphany Pizor wrote. In 2018, Congress passed the FAA Reauthorization Act, directing the agency to issue seat dimension rules regarding passenger safety.

Circuit Court of Appeals said an advocacy group, FlyersRights.org, had no right to force the FAA to adopt seating rules because it was not "clear and indisputable" that tight seating, while uncomfortable, was also dangerous. Congress had in 2018 given the FAA one year to establish minimum seating dimensions including pitch, the distance between seatbacks, that were "necessary" for passenger safety. "To be sure, many airline seats are uncomfortably small. "But it is not 'clear and indisputable' that airline seats have become dangerously small. Circuit Court of Appeals, No.

☆ Southwest explains its meltdown to Congress
▼ + stars: | 2023-02-09 | by ( Gregory Wallace | ) edition.cnn.com time to read: +4 min

Washington CNN —Congress is set to receive new evidence Thursday of internal chaos at Southwest Airlines over the Christmas holiday meltdown. The Senate Commerce committee is set to question Southwest executive Andrew Watterson, alongside Southwest pilot union president Casey Murray, Sharon Pinkerton of the Airlines for America trade group, Paul Hudson of Flyers’ Rights, and economist Clifford Winston of The Brookings Institution. It’s a mess down here.”A photograph of the message, which shows the extent of the airline’s breakdown, is included in testimony the Southwest Airlines Pilots Association union, SWAPA, plans to present at the hearing. Southwest CEO Bob Jordan apologized and the airline offered reimbursements for passengers’ costs, along with bonus points. The union criticized the airline for giving executives stock options in the wake of the meltdown while employees lost profit sharing pay because of the airline’s financial hit due to the meltdown.

☆ Southwest plans to tell Senate it's confident in its schedule after holiday meltdown
▼ + stars: | 2023-02-08 | by ( Leslie Josephs | ) www.cnbc.com time to read: +2 min

Southwest Airlines plans to apologize before a Senate panel on Thursday over the carrier's December meltdown that stranded hundreds of thousands of travelers around Christmas. "In hindsight, we did not have enough winter operational resilience," Chief Operating Officer Andrew Watterson said in written testimony, which was reviewed by CNBC, ahead of Senate Commerce Committee hearing. The debacle made for an $800 million pretax hit and drove the carrier to a net loss last quarter. Watterson plans to tell the committee that the carrier has made short-term improvements to communicate more easily with crews when things go wrong and has improved tools that keep track of the operation's stability. With those mitigation tools, "we are confident in our flight network and the schedules we have published for sale," Watterson plans to say, according to the testimony.

☆ Southwest pilots detail the Christmas meltdown chaos
▼ + stars: | 2023-02-08 | by ( Gregory Wallace | ) edition.cnn.com time to read: +4 min

CNN —Congress is set to receive new evidence Thursday of internal chaos at Southwest Airlines over the Christmas holiday meltdown. It’s a mess down here.”A photograph of the message, which shows the extent of the airline’s breakdown, is included in testimony the Southwest Airlines Pilots Association union, SWAPA, plans to present at a Senate Commerce committee hearing. “No updates here,” another cockpit computer message to pilots read. Southwest CEO Bob Jordan apologized and the airline offered reimbursements for passengers’ costs, along with bonus points. The union criticized the airline for giving executives stock options in the wake of the meltdown while employees lost profit sharing pay because of the airline’s financial hit due to the meltdown.

☆ Sanofi’s ailments are more than skin deep
▼ + stars: | 2023-02-03 | by ( ) www.reuters.com time to read: +2 min

LONDON, Feb 3 (Reuters Breakingviews) - Sanofi (SASY.PA) is battling multiple ailments. The $115 billion French pharma group on Friday forecast “low single digit” growth in earnings per share for 2023, disappointing analysts. Hence it’s more reliant on the star asthma and eczema drug Dupixent, which contributed nearly a fifth of Sanofi’s 43 billion euros of sales in 2022. Last August, $36 billion was wiped off Sanofi, GSK (GSK.L) and spinoff Haleon (HLN.L) shares on U.S. litigation fears. It currently trades on 10 times its forecast 2023 earnings, while Novartis (NOVN.S) trades on 13 times.

☆ Southwest to testify at U.S. Senate hearing after meltdown
▼ + stars: | 2023-02-03 | by ( David Shepardson | ) www.reuters.com time to read: +3 min

REUTERS/Alyssa Pointer/File PhotoWASHINGTON, Feb 3 (Reuters) - Southwest Airlines (LUV.N) Chief Operating Officer Andrew Watterson will testify on Feb. 9 before the U.S. Senate Commerce Committee after a holiday meltdown forced the budget carrier to cancel thousands of flights. The hearing titled "Strengthening Airline Operations and Consumer Protections" will also include Southwest Airlines Pilots Association President Captain Casey Murray, Sharon Pinkerton, a senior official with Airlines for America, an industry group, and Paul Hudson, who heads Flyers' Rights, a passenger advocacy organization. The hearing will review causes and impacts of recent air travel disruptions including the Southwest December holiday operational woes that resulted in more than 16,000 flight cancellations. Southwest Chief Executive Bob Jordan has repeatedly apologized for the mass cancellations and said the carrier is looking at all options to prevent a repeat. The U.S. Transportation Department (USDOT) is investigating whether Southwest engaged in "unrealistic scheduling of flights" in December.

☆ Southwest faces Senate hearing next week following holiday meltdown
▼ + stars: | 2023-02-03 | by ( Leslie Josephs | ) www.cnbc.com time to read: +2 min

John and Lori Ingoldsby, who drove to Denver after the first leg of their flight on Southwest Airlines was canceled, wait for a flight to finish their trip at Denver International Airport on December 28, 2022 in Denver, Colorado. Southwest Airlines ' chief operating officer, Andrew Watterson, will face questions from a Senate panel next Thursday about the carrier's holiday meltdown that stranded hundreds of thousands of travelers. Southwest said the hearing date overlapped with "a previous commitment" for CEO Bob Jordan. The incident has drawn increased scrutiny from Washington and capped a year of on-and-off disruptions in air travel, due to bad weather, staffing and technology issues. Sen. Maria Cantwell, D-Wash., the committee chair, had previously said she planned to hold a hearing on flight disruptions following Southwest's holiday travel chaos.

Labor shortagesAs the pandemic swooped in, air travel was among the industries most affected, as more than 90% of flights were grounded. Today, labor shortages exist throughout the economy, but the problem drags on in the air travel sector, where more extensive employee training is usually required. Steven Senne / APOutdated technology and infrastructureThere is near-universal agreement that the infrastructure underpinning segments of America's air travel system is outdated and vulnerable. Rep. Sam Graves, R-Montana, said the incident highlighted "a huge vulnerability in our air transportation system." Air travel should be predictable and consistent, and you shouldn’t have to wonder if air traffic control is going to be working today as you head to the airport.

☆ Sanofi CEO: Real breakthrough in RSV treatment is 'right around the corner'
▼ + stars: | 2023-01-19 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailSanofi CEO: Real breakthrough in RSV treatment is 'right around the corner'Paul Hudson, Sanofi CEO, joins 'Squawk Box' to discuss the company's product pipeline, Hudson's take on the trust the public have for vaccines and more.

Search resuls for: "Paul Hudson"

25 mentions found